Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Zynerba Pharmaceuticals, Inc. (ZYNE)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | | | | | | |
| Selling, general and administrative [+] | 4.0 | 3.4 | 3.2 | 3.5 | 3.7 | 3.8 | 3.8 | 3.9 |
| General and administrative | 4.0 | 3.4 | 3.2 | 3.5 | 3.7 | 3.8 | 3.8 | 3.9 |
| Research and development | 7.2 | 7.1 | 5.5 | 5.0 | 5.4 | 5.1 | 5.0 | 6.3 |
| EBITDA [+] | -11.1 | -10.4 | -8.6 | -8.4 | -9.1 | -8.8 | -8.8 | -10.1 |
| EBITDA growth | 21.5% | 17.8% | -1.6% | -16.8% | -6.8% | 13.0% | -13.4% | 10.6% |
| EBITDA margin | | | | | | | | |
| Depreciation and amortization | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| EBIT [+] | -11.1 | -10.5 | -8.7 | -8.5 | -9.2 | -8.9 | -8.8 | -10.2 |
| EBIT growth | 21.5% | 17.6% | -1.7% | -16.8% | -6.8% | 12.9% | -13.3% | 10.6% |
| EBIT margin | | | | | | | | |
| Interest income | 0.4 | 0.4 | 0.4 | 0.3 | 0.1 | 0.1 | 0.0 | 0.0 |
| Interest income | 0.4 | 0.4 | 0.4 | 0.3 | 0.1 | 0.1 | 0.0 | 0.0 |
| Other income (expense), net [+] | -0.1 | -0.1 | 0.3 | -0.4 | -0.8 | 0.3 | 0.0 | -0.4 |
| Gain (loss) on foreign currency transactions | -0.1 | -0.1 | 0.3 | -0.4 | -0.8 | 0.3 | 0.0 | -0.4 |
| Pre-tax income | -10.8 | -10.1 | -8.0 | -8.7 | -9.9 | -8.5 | -8.8 | -10.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -10.8 | -10.1 | -8.0 | -8.7 | -9.9 | -8.5 | -8.8 | -10.6 |
| Net margin | | | | | | | | |
| |
| Basic EPS [+] | ($0.21) | ($0.21) | ($0.19) | ($0.20) | ($0.24) | ($0.21) | ($0.22) | ($0.26) |
| Growth | -9.7% | -0.9% | -16.3% | -24.9% | -4.2% | 6.0% | -36.9% | -14.7% |
| Diluted EPS [+] | ($0.21) | ($0.21) | ($0.19) | ($0.20) | ($0.24) | ($0.21) | ($0.22) | ($0.26) |
| Growth | -9.7% | -0.9% | -16.3% | -24.9% | -4.2% | 6.0% | -36.9% | -14.7% |
| |
| Shares outstanding (basic) [+] | 50.2 | 48.4 | 42.7 | 43.7 | 41.4 | 40.3 | 39.3 | 40.1 |
| Growth | 21.1% | 20.2% | 8.7% | 9.1% | 3.3% | 0.6% | 45.3% | 37.1% |
| Shares outstanding (diluted) [+] | 50.2 | 48.4 | 42.7 | 43.7 | 41.4 | 40.3 | 39.3 | 40.1 |
| Growth | 21.1% | 20.2% | 8.7% | 9.1% | 3.3% | 0.6% | 45.3% | 37.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|